210 related articles for article (PubMed ID: 33677931)
1. Lactate Dehydrogenase A as a Potential New Biomarker for Thyroid Cancer.
Ban EJ; Kim D; Kim JK; Kang SW; Lee J; Jeong JJ; Nam KH; Chung WY; Kim K
Endocrinol Metab (Seoul); 2021 Feb; 36(1):96-105. PubMed ID: 33677931
[TBL] [Abstract][Full Text] [Related]
2. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.
Feng C; Gao Y; Wang C; Yu X; Zhang W; Guan H; Shan Z; Teng W
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1524-33. PubMed ID: 23846818
[TBL] [Abstract][Full Text] [Related]
3. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
Choi YW; Kim YH; Lee J; Soh EY; Park TJ; Kim JH
Hum Pathol; 2015 Oct; 46(10):1557-65. PubMed ID: 26297257
[TBL] [Abstract][Full Text] [Related]
4. Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data.
Chai YJ; Yi JW; Jee HG; Kim YA; Kim JH; Xing M; Lee KE
PLoS One; 2016; 11(7):e0159235. PubMed ID: 27410688
[TBL] [Abstract][Full Text] [Related]
5. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
6. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
[TBL] [Abstract][Full Text] [Related]
7. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
8. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
9. Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation.
Stojanović S; Šelemetjev S; Đorić I; Rončević J; Janković Miljuš J; Živaljević V; Išić Denčić T
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1835-1842. PubMed ID: 32651027
[TBL] [Abstract][Full Text] [Related]
10. LGR5 is associated with tumor aggressiveness in papillary thyroid cancer.
Michelotti G; Jiang X; Sosa JA; Diehl AM; Henderson BB
Oncotarget; 2015 Oct; 6(33):34549-60. PubMed ID: 26416247
[TBL] [Abstract][Full Text] [Related]
11. Deregulated expression of Aurora kinases is not a prognostic biomarker in papillary thyroid cancer patients.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Falvo L; De Vito C; Catania A; Tartaglia F; Mocini R; Coccaro C; Alessandrini S; Barollo S; Mian C; Antonelli A; De Antoni E; D'Armiento M; Ulisse S
PLoS One; 2015; 10(3):e0121514. PubMed ID: 25807528
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J
J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
[TBL] [Abstract][Full Text] [Related]
14. In papillary thyroid carcinoma, TIMP-1 expression correlates with BRAF (V600E) mutation status and together with hypoxia-related proteins predicts aggressive behavior.
Ilie MI; Lassalle S; Long-Mira E; Hofman V; Zangari J; Bénaim G; Bozec A; Guevara N; Haudebourg J; Birtwisle-Peyrottes I; Santini J; Brest P; Hofman P
Virchows Arch; 2013 Sep; 463(3):437-44. PubMed ID: 23893334
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.
Pasquali D; Santoro A; Bufo P; Conzo G; Deery WJ; Renzullo A; Accardo G; Sacco V; Bellastella A; Pannone G
Thyroid; 2011 Apr; 21(4):391-9. PubMed ID: 21385081
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma.
Yin DT; Xu J; Lei M; Li H; Wang Y; Liu Z; Zhou Y; Xing M
Oncotarget; 2016 Feb; 7(5):5830-41. PubMed ID: 26716505
[TBL] [Abstract][Full Text] [Related]
17. The relationship between BRAFV600E, NF-κB and TgAb expression in papillary thyroid carcinoma.
Li W; Ming H; Sun D; Li W; Wang D; Zhang G; Tan J
Pathol Res Pract; 2017 Mar; 213(3):183-188. PubMed ID: 28214213
[TBL] [Abstract][Full Text] [Related]
18. Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer.
Song YS; Yoo SK; Kim HH; Jung G; Oh AR; Cha JY; Kim SJ; Cho SW; Lee KE; Seo JS; Park YJ
Endocr Relat Cancer; 2019 Jun; 26(6):629-641. PubMed ID: 30999281
[TBL] [Abstract][Full Text] [Related]
19. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
20. BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB.
Zhou D; Li Z; Bai X
Med Sci Monit; 2017 Nov; 23():5321-5329. PubMed ID: 29117154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]